Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Viridian Therapeutics, Inc. Common Stock

VRDN

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Last trade $29.62
Day change -$0.185 (-0.62%)
Day range $29.29 – $30.33
Volume 698,237
Market cap $3.38B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.38B
Price / earnings
—
Price / book
5.83×
Price / sales
128.63×
EV / sales
135.89×
EV / EBITDA
-7.63×

Profitability

Earnings per share
-$3.50
Return on assets
-38.63%
Return on equity
-68.43%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.63×
Current ratio
14.46×
Quick ratio
14.46×
Cash ratio
2.47×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$343.44M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VRDN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$25.75M$284K$141K$132K$70.57M$75K$72K$72K
Cost of revenue$1.53M$0$0$0$0$0$0$0
Gross profit$24.23M$284K$141K$132K$70.57M$75K$72K$72K
Selling, general and administrative$57.61M$54.98M$38.68M$33.67M$24.32M$20.22M$17.1M$15.58M
Research and development$70.09M$71.58M$77.63M$89.21M$86.26M$86.63M$76.84M$71.96M
Total operating expenses$127.7M$126.55M$116.98M$122.88M$110.58M$106.84M$93.97M$87.54M
Operating income-$103.48M-$126.27M-$116.84M-$122.75M-$40.01M-$106.77M-$93.9M-$87.47M
Interest expense-$9.27M-$8.31M-$3.46M-$3.28M-$560K-$514K-$550K-$517K
Income before taxes-$101.21M-$127.12M-$104.9M-$120.36M-$34.6M-$100.74M-$86.91M-$79.73M
Income taxes$0$0$0$0$0$0$0$0
Net income-$101.21M-$127.12M-$104.9M-$120.36M-$34.6M-$100.74M-$86.91M-$79.73M
Net income attributable to common shareholders-$91.44M-$112.82M-$92.03M-$101.07M-$28.17M-$81.98M-$70.69M-$64.46M
EBITDA-$103.13M-$126.15M-$116.72M-$122.63M-$39.9M-$106.65M-$93.79M-$87.35M
Basic earnings per share-$0.81-$1.05-$0.90-$1.07-$0.34-$1.00-$0.87-$0.80
Diluted earnings per share-$0.81-$1.05-$0.90-$1.07-$0.34-$1.00-$0.87-$0.80

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know

Viridian Therapeutics (VRDN) has gained 55.7% over the past four weeks and closed at $28.55. Wall Street analysts have set a mean price target of $39.88, indicating 39.7% upside potential. The stock has a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions, with the consensus estimate increasing 3.1% over the past month. However, the article cautions that price targets alone should not be the sole basis for investment decisions.

Zacks Investment Research

Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates

Arvinas (ARVN) reported a quarterly loss of $0.82 per share, slightly missing the consensus estimate of $0.80, with revenues of only $0.5 million versus expectations of $25.51 million. The company's stock has declined 36.6% year-to-date, significantly underperforming the S&P 500's 10.2% gain. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

The Motley Fool

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

HighVista Strategies sold 238,243 shares of Viridian Therapeutics (worth ~$7.08 million) in Q1 2026, reducing its position by $8.97 million when accounting for stock price movements. The sale may reflect profit-taking ahead of the company's June 30 FDA decision on its lead therapy veligrotug. Despite recent stock volatility following Phase 3 data that beat expectations, Viridian remains positioned as a potential commercial player in the thyroid eye disease market with its subcutaneous candidate elegrobart.

The Motley Fool

Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know

Kopp Family Office reduced its Viridian Therapeutics stake by 117,878 shares ($3.5M) in Q1 2026, cutting the position from 3.4% to 0.7% of AUM. The move appears prescient as Viridian shares have fallen 50% since mid-March following disappointing Phase 3 data for elegrobart and stronger competing results from Amgen's Tepezza variant, raising questions about market differentiation for the clinical-stage biotech.

GlobeNewswire Inc.

J.Jill, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Johnson Fistel, PLLC is investigating potential securities fraud claims on behalf of investors in J.Jill, RH, and Viridian Therapeutics. The J.Jill investigation was prompted by the company's March 31, 2026 earnings disclosure revealing poor holiday assortment performance, increased competitive promotions, and customer migration toward discounted pricing, raising questions about compliance with federal securities laws.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 13, 20201-for-15reverse split
Nov 7, 20161-for-15reverse split